KR102398032B9 - 암 치료를 위한 5''-뉴클레오티다아제 변이체 - Google Patents

암 치료를 위한 5''-뉴클레오티다아제 변이체

Info

Publication number
KR102398032B9
KR102398032B9 KR1020200122164A KR20200122164A KR102398032B9 KR 102398032 B9 KR102398032 B9 KR 102398032B9 KR 1020200122164 A KR1020200122164 A KR 1020200122164A KR 20200122164 A KR20200122164 A KR 20200122164A KR 102398032 B9 KR102398032 B9 KR 102398032B9
Authority
KR
South Korea
Prior art keywords
nucleotidas
variants
treatment cancer
cancer
treatment
Prior art date
Application number
KR1020200122164A
Other languages
English (en)
Other versions
KR20220039256A (ko
KR102398032B1 (ko
Inventor
이현철
구봉성
서형종
김진숙
Original Assignee
비피진 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비피진 주식회사 filed Critical 비피진 주식회사
Priority to KR1020200122164A priority Critical patent/KR102398032B1/ko
Priority to PCT/KR2021/011702 priority patent/WO2022065725A1/ko
Priority to JP2023517328A priority patent/JP2023542142A/ja
Priority to EP21872755.0A priority patent/EP4183877A1/en
Priority to US18/021,092 priority patent/US20230293571A1/en
Priority to CN202180054385.8A priority patent/CN116194117A/zh
Publication of KR20220039256A publication Critical patent/KR20220039256A/ko
Application granted granted Critical
Publication of KR102398032B1 publication Critical patent/KR102398032B1/ko
Publication of KR102398032B9 publication Critical patent/KR102398032B9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03035—Thymidylate 5'-phosphatase (3.1.3.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020200122164A 2020-09-22 2020-09-22 암 치료를 위한 5''-뉴클레오티다아제 변이체 KR102398032B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020200122164A KR102398032B1 (ko) 2020-09-22 2020-09-22 암 치료를 위한 5''-뉴클레오티다아제 변이체
PCT/KR2021/011702 WO2022065725A1 (ko) 2020-09-22 2021-08-31 5'-뉴클레오티다아제 변형 단백질을 암호화하는 암 치료를 위한 폴리뉴클레오티드
JP2023517328A JP2023542142A (ja) 2020-09-22 2021-08-31 ５’－ヌクレオチダーゼ変形タンパク質を暗号化するがん治療のためのポリヌクレオチド
EP21872755.0A EP4183877A1 (en) 2020-09-22 2021-08-31 Polynucleotide for cancer treatment, encoding 5'-nucleotidase modified protein
US18/021,092 US20230293571A1 (en) 2020-09-22 2021-08-31 Polynucleotide for cancer treatment, encoding 5'-nucleotidase modified protein
CN202180054385.8A CN116194117A (zh) 2020-09-22 2021-08-31 编码5'-核苷酸酶修饰蛋白的癌症治疗用多核苷酸

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200122164A KR102398032B1 (ko) 2020-09-22 2020-09-22 암 치료를 위한 5''-뉴클레오티다아제 변이체

Publications (3)

Publication Number Publication Date
KR20220039256A KR20220039256A (ko) 2022-03-29
KR102398032B1 KR102398032B1 (ko) 2022-05-19
KR102398032B9 true KR102398032B9 (ko) 2022-09-30

Family

ID=80846768

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200122164A KR102398032B1 (ko) 2020-09-22 2020-09-22 암 치료를 위한 5''-뉴클레오티다아제 변이체

Country Status (6)

Country Link
US (1) US20230293571A1 (ko)
EP (1) EP4183877A1 (ko)
JP (1) JP2023542142A (ko)
KR (1) KR102398032B1 (ko)
CN (1) CN116194117A (ko)
WO (1) WO2022065725A1 (ko)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693385A4 (en) 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
EP2995315B1 (en) * 2009-05-15 2023-12-27 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
CN110386984B (zh) * 2018-04-17 2022-04-22 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用

Also Published As

Publication number Publication date
WO2022065725A1 (ko) 2022-03-31
CN116194117A (zh) 2023-05-30
US20230293571A1 (en) 2023-09-21
EP4183877A1 (en) 2023-05-24
JP2023542142A (ja) 2023-10-05
KR20220039256A (ko) 2022-03-29
KR102398032B1 (ko) 2022-05-19

Similar Documents

Publication Publication Date Title
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
IL290415A (en) Compounds with deuterium for use in cancer treatment
ZA202206743B (en) Therapy for the treatment of cancer
IL285155A (en) Therapy using metal chelators for cancer treatment
IL312171A (en) Innovative use of the quinazolinone compound for cancer treatment
IL307964A (en) Combined treatment for cancer
KR102398032B9 (ko) 암 치료를 위한 5''-뉴클레오티다아제 변이체
WO2009038771A3 (en) Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers
IL286680A (en) A drug to treat cancer
GB202016425D0 (en) Treatment regimens for parkinson's disease
GB202003722D0 (en) Treatment
GB201919316D0 (en) Polymeric nanoparticles for enhanced cancer treatment
GB202002711D0 (en) Treatment
GB202315849D0 (en) Improved cancer treatment
GB202118025D0 (en) Cancer treatment
GB202111930D0 (en) Cancer treatment
GB202010314D0 (en) Cancer treatment
GB202303784D0 (en) Cancer treatment
GB202217305D0 (en) Cancer treatment
IL305780A (en) Cancer treatment methods
GB202211123D0 (en) Cancer treatment
GB202210038D0 (en) Cancer treatment
GB202206948D0 (en) Cancer treatment
GB201907204D0 (en) Cancer treatment 3
GB201907150D0 (en) Cancer treatment 2

Legal Events

Date Code Title Description
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
G170 Re-publication after modification of scope of protection [patent]